SCHEMBL309991

SCHEMBL309991

N#Cc1ccc(CBr)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.42
FFAR4 Q5NUL3 3/20 0.42
CTSB P07858 1/20 0.37
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
NR3C2 P08235 1/20 0.37
CYP19A1 P11511 2/20 0.37
GSK3B P49841 2/20 0.36
KIF11 P52732 1/20 0.36
P2RX7 Q99572 1/20 0.36
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
EGLN2 Q96KS0 3/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
MPO P05164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413229 1.00 FFAR1 (0.42) FFAR1FFAR4CTSBNR3C1PGR
SCHEMBL5538330 0.96 FFAR1 (0.40) FFAR1FFAR4CTSBNR3C1PGR
Dimethyl Sulfoxide SCHEMBL28678614 0.90 FFAR1 (0.40) FFAR1FFAR4CTSBNR3C1PGR
SCHEMBL29738062 0.85 FFAR1 (0.40) FFAR1FFAR4CTSBNR3C1PGR
SCHEMBL27485764 0.85 FFAR1 (0.46) FFAR1FFAR4CTSBNR3C1PGR
SCHEMBL29413212 0.84 MPO (0.43) FFAR1FFAR4GSK3BKIF11KCNH2
SCHEMBL411021 0.84 MPO (0.43) FFAR1FFAR4GSK3BKIF11KCNH2
SCHEMBL7770769 0.82 FFAR1 (0.43) FFAR1FFAR4CTSBNR3C1PGR
SCHEMBL3872780 0.81 GSK3B (0.39) GSK3BHTR2AKCNH2
SCHEMBL24136215 0.80 FFAR1 (0.45) FFAR1FFAR4CTSBNR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 652 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452952-A1 A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) 2024-10-30 EP claimed
CN-118451062-A Preparation and use of quinazolinediones 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) 2024-08-06 CN claimed
CN-116640106-B Phenylpiperazine compound and preparation method and application thereof 郑州大学 2024-03-08 CN claimed
CN-113816874-B Process method for synthesizing 4-cyano-2-fluorobenzyl alcohol 大连双硼医药化工有限公司 2024-01-26 CN claimed
CN-115246795-B Isoxazoline compound containing ether structure at 4-phenyl para-position, preparation method thereof and application thereof as insecticidal and bactericidal agent 瑞普(天津)生物药业有限公司 2024-01-02 CN claimed
CN-116640106-A Phenylpiperazine compound and preparation method and application thereof 郑州大学 2023-08-25 CN claimed
WO-2023119320-A1 A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2023-06-29 WO claimed
CN-115246795-A Isoxazoline compound with 4-phenyl para-position containing ether structure, preparation thereof and application thereof as insecticide and bactericide 瑞普(天津)生物药业有限公司 2022-10-28 CN claimed
CN-113816874-A Process method for synthesizing 4-cyano-2-fluorobenzyl alcohol 大连双硼医药化工有限公司 2021-12-21 CN claimed
CN-122080069-A Phospholipid compounds and uses thereof 2026-05-26 CN disclosed
EP-3887359-B1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING UNIV COPENHAGEN (DK) 2026-05-06 EP disclosed
US-12595249-B2 Aryl ether-substituted heterocyclic compounds as glpir agonists MINDRANK AI LTD. (CN) 2026-04-07 US disclosed
US-12595251-B2 Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2026-04-07 US disclosed
EP-4271674-B9 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-03-11 EP disclosed
WO-1998016526-A1 TETRAHYDRO-6H-PYRAZINO[1,2-B]ISOQUINOLINE 1,4-DIONES AS APOPROTEIN B-100 INHIBITORS GLAXO GROUP LIMITED (GB) 1998-04-23 WO disclosed
WO-1996038426-A1 NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-05 WO disclosed
WO-1995014683-A1 NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-06-01 WO disclosed
US-4784471-A LIQUID CRYSTALS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1988-11-15 US disclosed
EP-0211876-A1 FLUOROBENZENE DERIVATIVES MERCK PATENT GmbH (DE) 1987-03-04 EP disclosed
WO-1986004895-A1 FLUOROBENZENE DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1986-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595249-B2 Aryl ether-substituted heterocyclic compounds as glpir agonists GLP1R, GIPR, GCGR FFAR1 40/4885FFAR4 119/4885CTSB 3932/4885
US-12595251-B2 Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics CLIC1, CBR3, CBR1 FFAR1 657/4885FFAR4 1487/4885CTSB 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.